Isolated hyperbilirubinemia following standard dose cytosine arabinoside in a patient with relapsed acute myeloid leukemia.
Altundag
Ozden
O
Altundag
Kadri
K
Celik
Ismail
I
Turker
Alev
A
Kars
Ayse
A
D000208:Acute Disease; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects* / Q000627:therapeutic use; D003561:Cytarabine / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006932:Hyperbilirubinemia / Q000139:chemically induced*; D007951:Leukemia, Myeloid / Q000097:blood / Q000188:drug therapy*; D008875:Middle Aged; D012008:Recurrence
D000964:Antimetabolites, Antineoplastic; D003561:Cytarabine